Eurofins Alphora Completes Pilot Scale mAbs Development Facility

Eurofins CDMO Alphora Inc., a CDMO based in Mississauga, Canada, has successfully completed its pilot-scale biologics development facility. The 3,300 sq.-ft. facility is dedicated to the development and scaling of monoclonal antibodies (mAbs) and other mammalian-based therapeutic proteins. The facilities offer upstream and downstream development, process design, analytical development, GMP QC testing, GMP Cell-Based Assays, and scale-up capacity to 200L for preclinical and phase I supply.

The facility is equipped with cutting-edge technology and can accommodate diverse batch sizes, both fedbatch and perfusion. The analytical laboratory offers a wide range of analytical testing and bio-assays for both GMP and non-GMP applications, supporting process and drug candidate characterization. This integrated service aims to enable clients to streamline timelines and reduce development costs in manufacturing biologic drug candidates.

Together with experience in linker and warhead development through its active pharmaceutical ingredients (API) and highly potent active pharmaceutical ingredients (HPAPI) services, the added biologics capacity supports fully integrated conjugation services for antibody drug conjugate (ADC) candidate development.